NEO NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.…
Industry Peers
Diagnostics & ResearchKey Statistics
About NeoGenomics (NASDAQ: NEO)
›
NeoGenomics (NASDAQ: NEO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 2,500 employees.
The shares were at 15.09 USD on 19 November 2026, up 45.1% over 52 weeks. Its 52-week range is 7.070 USD to 20.15 USD: the price is 25.1% below the high and 113.4% above the low.
Its market capitalisation is 1.95B USD.
NeoGenomics reports return on equity of -12.9%, an operating margin of -5.5% and revenue up 11.4% year over year.
Its debt exceeds its cash by 309.86M USD, a debt-to-equity ratio of 0.49. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 10 analysts cover the stock; their mean price target of 23.40 USD is 55.1% above the current price. The next earnings report is expected on 16 February 2027.